Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series

por Inaba‐Higashiyama, Ryoko, Yoshida, Tatsuya, Jo, Hitomi, Shirasawa, Masayuki, Motoi, Noriko, Ohe, Yuichiro
Publicado 2020